Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cRGDwV
- Development stage
- Preclinical
- Modality
- Peptides
01
Overview
cRGDwV is a cyclic Arg-Gly-Asp (RGD) peptide derivative containing aromatic amino acids. It has demonstrated inhibitory effects on non-small cell lung cancer (NSCLC) cell growth, TGF-β1-induced epithelial-to-mesenchymal transition (EMT), and invasion. These effects have been observed particularly in gefitinib-resistant NSCLC A549 (A549GR) cells, where cRGDwV also inhibits mesenchymal marker expression, migration, and invasion. As a cyclic RGD peptide, its mechanism of action is likely through binding to integrin receptors, thereby modulating cell adhesion and signaling pathways involved in cancer progression and resistance.
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)Integrin (Integrin family)Neuraminidase
Beyond the preview
Go deeper on cRGDwV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cRGDwV.